Strides Pharma Science Ltd
NSE:STAR

Watchlist Manager
Strides Pharma Science Ltd Logo
Strides Pharma Science Ltd
NSE:STAR
Watchlist
Price: 950.65 INR 5.54% Market Closed
Market Cap: 87.6B INR
Section:
 

Relative Value

The Relative Value of one STAR stock under the Base Case scenario is hidden INR. Compared to the current market price of 950.65 INR, Strides Pharma Science Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

STAR Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1.8
P/S
P/S
Price to Sales
1.8
vs History
34
vs Industry
61
Median 3Y
1.6
Median 5Y
1.5
Industry
2.6
Forward
1.7
More Details
20.9
P/E
P/E
Price to Earnings
20.9
vs History
28
vs Industry
19
Median 3Y
1.7
Median 5Y
-7.6
Industry
21.4
Forward
16
More Details
11.9
P/OCF
P/OCF
Price to OCF
11.9
vs History
49
vs Industry
42
Median 3Y
12.1
Median 5Y
12.1
Industry
16.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
1
Median 3Y
-35.3
Median 5Y
-15.9
Industry
22.8
More Details
3
P/B
P/B
Price to Book Value
3
vs History
20
vs Industry
25
Median 3Y
2.9
Median 5Y
2.5
Industry
2.2
More Details
1.8
EV/S
EV/S
Enterprise Value to Sales
1.8
vs History
46
vs Industry
59
Median 3Y
1.7
Median 5Y
1.7
Industry
2.9
Forward
1.7
More Details
3.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.1
vs History
49
vs Industry
64
Median 3Y
2.8
Median 5Y
3.1
Industry
5.5
More Details
9.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.6
vs History
69
vs Industry
38
Median 3Y
9.7
Median 5Y
11.6
Industry
13
Forward
8.7
More Details
12.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.4
vs History
66
vs Industry
37
Median 3Y
15.6
Median 5Y
15.7
Industry
16.5
Forward
8.9
More Details
12.1
EV/OCF
EV/OCF
Enterprise Value to OCF
12.1
vs History
61
vs Industry
41
Median 3Y
12.4
Median 5Y
13.2
Industry
15.6
More Details
21.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
21.1
vs History
31
vs Industry
30
Median 3Y
16.3
Median 5Y
14.7
Industry
18.7
More Details
1.7
EV/IC
EV/IC
Enterprise Value to IC
1.7
vs History
25
vs Industry
44
Median 3Y
1.4
Median 5Y
1.4
Industry
1.9
More Details

Multiples Across Competitors

STAR Competitors Multiples
Strides Pharma Science Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Strides Pharma Science Ltd
NSE:STAR
83B INR 1.8 20.9 9.6 12.4
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
259.1B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
208.8B GBP 4.8 30 108.3 158.5
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
CH
Novartis AG
SIX:NOVN
207.2B CHF 4.7 18.2 11.5 14.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.8 14.5 10.1 11.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
IN
Strides Pharma Science Ltd
NSE:STAR
Average P/E: 23.9
20.9
-37%
N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30
37%
0.8
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
CH
Novartis AG
SIX:NOVN
18.2
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
14.5
3%
4.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Strides Pharma Science Ltd
NSE:STAR
Average EV/EBITDA: 400.6
9.6
21%
0.5
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.1
1%
10.1
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Strides Pharma Science Ltd
NSE:STAR
Average EV/EBIT: 1 713.2
12.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
CH
Novartis AG
SIX:NOVN
14.9
12%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
STAR intrinsic value, competitors valuation, and company profile.
DCF Valuation
STAR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
STAR stock valuation using valuation multiples.
Wall Street Estimates
STAR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
STAR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.